+62%

est. 2Y upside i

HealthcareSeries D+

Rank

#804

Sector

Healthcare Technology / SaaS

Est. Liquidity

~1Y

Data Quality

Data: High

Weave is a public healthcare SaaS company trading at 2.3x revenue, well below the 2x-5x comp range.

Last updated: July 19, 2026

Bull (20%)+116%

If AI adoption and payments growth accelerate, multiple could expand to 4x forward revenue. Projected market cap of $1.31B yields 116% net upside after 5% dilution.

Base (50%)+89%

Multiple converges to 3.5x in line with public comps (VEEV, PHR, HSTM). Projected revenue of $327M supports $1.15B market cap, delivering 89% net upside.

Bear (30%)-19%

If growth slows further or competition intensifies, multiple could compress to 1.5x. Projected market cap of $491M yields -19% return net of dilution.

Est. time to liquidity~1.0 years

Preference Stack Risk

low

Funding Intensity

2710%

No liquidation preference as company is public; all shares are common.

Dilution Risk

low

As a public company, future equity issuances are limited; assumed 5% dilution from employee grants and potential secondary offerings.

Secondary Liquidity

active

Shares are publicly traded on NYSE (WEAV) providing immediate liquidity post-vesting.

Other — 12 roles

View all 12 open roles at Weave →

Last updated: March 10, 2026

Questions to Ask at the Interview

Strategic questions based on Weave's data — designed to show you've done your homework.

  • 1

    “How does Weave maintain a competitive edge against larger incumbents like Zendesk in the healthcare vertical?”

  • 2

    “What is the gross margin trajectory as payments revenue grows vs subscription revenue?”

  • 3

    “How will the AI receptionist product impact customer acquisition costs and retention over the next 2 years?”

Community

Valuation Sentiment

Our model estimates +62% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.